Evaluating the safety of Fycompa injection for seizures

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the safety of Fycompa injection in individuals with epilepsy, specifically those experiencing partial-onset seizures or primary generalized tonic-clonic seizures. Participants aged 4 years and older with partial-onset seizures and those aged 12 years and older with tonic-clonic seizures will be included. The study is observational and focuses on patients receiving Fycompa for the first time, without specific exclusion criteria, reflecting real-world clinical practice.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants with epilepsy who received the Fycompa for injection for the first time will be included.

Exclusion Criteria:

* The exclusion criteria will not be specified in particular because this survey will be conducted in daily clinical practice.

Where it's running

• 1
  Tokyo, Japan Recruiting

Study contacts

• Study coordinator: Eisai Inquiry Service
• Email: eisai-chiken_hotline@hhc.eisai.co.jp
• Phone: 0120-419-497

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating XEN1101 for treating primary generalized tonic-clonic seizures

  This study is testing a new medication called XEN1101 to see if it can help people aged 12 and older with primary generalized tonic-clonic seizures who are still having seizures despite taking other medications.

  Recruiting at 99 sites Phase 3 Xenon Pharmaceuticals Inc. · Mobile, Alabama and 140 other locations · NCT05667142

• Lecanemab-irmb in Real-World Use for Alzheimer’s Disease

  This study tests the safety of lecanemab-irmb in people with Alzheimer’s disease by looking at real-world brain-image changes and related events.

  Recruiting Eisai Inc. · Nutley, New Jersey · NCT07821658

• E2086: See if it interacts with other drugs when taken with common medications

  This small early study tests whether E2086 changes the way certain medicines work when taken together in healthy adults.

  Recruiting Phase 1 Eisai Inc. · Austin, Texas · NCT07766369

• Post-authorization registry of people treated with LEQEMBI

  This registry will track how often and how severe known brain imaging side effects occur in people with Alzheimer's who are taking LEQEMBI in routine clinical care in Canada.

  Recruiting at 3 sites Eisai Inc. · Calgary, Alberta and 16 other locations · NCT07762092

• E6742 for adults with active systemic lupus erythematosus

  This trial tests whether different doses of E6742 help adults with active systemic lupus erythematosus reduce disease activity while on a low dose of oral steroids by Week 24.

  Recruiting at 46 sites Phase 2 Eisai Inc. · Bengbu, Anhui and 53 other locations · NCT07515014

• E2086 for adults with narcolepsy: find the best dose compared with placebo

  This study tests different doses of E2086 against placebo in adults with narcolepsy to see if it reduces daytime sleepiness.

  Recruiting at 2 sites Phase 2 Eisai Inc. · Santa Ana, California and 56 other locations · NCT07493265

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.